Valiant OrganicsQ4 FY22

Valiant Organics Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹348.2P/E: 17.5Market Cap: ₹976 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • FY23 volume expected around 60,000-65,000 tons, up from ~50,000 tons (Page 14-15).
  • Hydrogenation volumes (including PAP and OAP) to increase, with PAP ramping from 300 to 500 tons/month in H1 FY23 and targeted 1000 tons/month by end of FY23 (Pages 14, 18-19).
  • Continuous process at PAP expected to improve margins and volumes further beyond 500 tons/month (Page 19).
  • Sales guidance: FY23 standalone revenue target ~1200-1250 crores; FY24 target ~1400 crores (Page 18).
  • EBITDA margin expected to improve to around 15% at 500 tons/month PAP volume and higher with continuous process (Page 19).
  • Revenue growth guidance: 35-40% growth next year (FY23), followed by 15-20% growth in the subsequent year (Page 18).
  • New products OAP and pharma intermediates expected to start contributing from Q2 FY23, supporting volume growth (Page 8).

See what Valiant Organics management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No new long-term borrowings are planned for the near future.
  • The company expects to fund its CAPEX internally without raising new debt.
  • Some short-term loans for working capital may fluctuate, but no major increase in debt expected.
  • Debt to equity ratio is currently comfortable at about 25%.
  • Management aims to reduce short-term loans as working capital requirements normalize.
  • No mention of any planned equity fundraising in the call.

See what Valiant Organics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • For FY23, the planned CAPEX is around Rs. 60-70 crores.
  • Major portion allocated for Ahmedabad plant redevelopment.
  • Additional CAPEX for pharma intermediates expansion and moving PAP (para-aminophenol) production to continuous processing.
  • The continuous process at PAP will require further CAPEX as part of scaling up production.
  • The pharma intermediates project has incurred about Rs. 55 crores out of a Rs. 60 crore budget but is not yet commercialized.
  • OAP (ortho-aminophenol) project, with a budget around Rs. 30 crores, is also in progress but not yet commercialized.
  • Continuous process for PAP aims to increase production capacity beyond the current batch process limit of 500 tons/month.
  • No major new large ticket investments are planned until stabilization of ongoing projects.

Track Valiant Organics — get its next earnings analysis in your feed

How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisValiant Organics
Rev 3Mar 1

How does Valiant Organics rank in Chemicals & Petrochemicals?

Compare Valiant Organics against every Chemicals & Petrochemicals company (Q4 FY22) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →